Artificial intelligence-enabled coronary plaque quantification for personalized risk assessment and lipid-lowering therapy: Insights from the FISH&CHIPS study✰
Shyon Parsa(Cardiovascular Institute of the South), F. Gamboa Rodriguez(Stanford Health Care), J. Wendy Bell(University of Liverpool), Campbell Rogers(HeartFlow (United States)), Allison W. Peng(Johns Hopkins University), Laurence P. Tidbury(University of Liverpool), Souma Sengupta(HeartFlow (United States)), E D Nicol(King's College - North Carolina), T A Fairbairn(University of Liverpool), Jonathan Weir-McCall(King's College - North Carolina), Seth S. Martin(Johns Hopkins University), Sarah A. Mullen(HeartFlow (United States))
Cited by 2
Related Papers
Inflammation and Restenosis in the Stent Era
|Arteriosclerosis Thrombosis and Vascular Biology|2002|622
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI
|Nature Medicine|2022|499
1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT
|JACC. Cardiovascular imaging|2019|309
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry
|European Heart Journal|2018|305
Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies
|Journal of the American College of Cardiology|2020|289